Wall Street brokerages predict that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post ($1.40) earnings per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.15) and the lowest estimate coming in at ($1.67). Alnylam Pharmaceuticals posted earnings of ($1.32) per share in the same quarter last year, which indicates a negative year over year growth rate of 6.1%. The firm is expected to announce its next earnings report on Wednesday, February 14th.
On average, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($5.29) per share for the current fiscal year, with EPS estimates ranging from ($5.40) to ($5.08). For the next year, analysts anticipate that the company will report earnings of ($5.78) per share, with EPS estimates ranging from ($6.61) to ($4.90). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. During the same period last year, the firm posted ($1.21) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 24.8% compared to the same quarter last year.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up $1.02 on Tuesday, reaching $129.07. The company’s stock had a trading volume of 796,400 shares, compared to its average volume of 732,122. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a 12-month low of $35.98 and a 12-month high of $147.63. The firm has a market capitalization of $12,691.56, a price-to-earnings ratio of -24.58 and a beta of 2.98.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 33,666 shares of the company’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $121.46, for a total value of $4,089,072.36. Following the completion of the transaction, the executive vice president now owns 45,201 shares in the company, valued at approximately $5,490,113.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total value of $2,600,000.00. Following the completion of the transaction, the director now owns 20,000 shares of the company’s stock, valued at approximately $2,600,000. The disclosure for this sale can be found here. Insiders have sold 274,075 shares of company stock valued at $35,356,089 in the last quarter. 4.30% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the business. QS Investors LLC grew its stake in Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the period. The Manufacturers Life Insurance Company grew its stake in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 167 shares during the period. Neuberger Berman Group LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $229,000. Fayerweather Charles bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $230,000. Finally, Watch Point Trust Co bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $235,000. Hedge funds and other institutional investors own 88.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2018/01/16/1052730.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.